Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors

BACKGROUND: Activating mutations in JAK1 and JAK2 have been described in patients with various hematologic malignancies including acute lymphoblastic leukemia and myeloproliferative neoplasms, leading to clinical trials with JAK inhibitors. While there has been a tremendous effort towards the develo...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Hornakova, Tekla, Springuel, Lorraine, Devreux, Julien, Dusa, Alexandra, Constantinescu, Stefan N., Knoops, Laurent, Renauld, Jean-Christophe
Formato: Artigo
Lenguaje:Inglês
Publicado: Ferrata Storti Foundation 2011
Materias:
Original Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3105646/
https://ncbi.nlm.nih.gov/pubmed/21393331
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2010.036350
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares